GLP-1 medications are linked to a modestly higher rate of gallstones and gallbladder inflammation, partly because faster weight loss raises gallstone risk on its own. These events are uncommon, and knowing the warning signs helps you act early.
GLP-1 medications such as semaglutide and tirzepatide are associated with a higher rate of gallbladder problems, mainly gallstones and inflammation of the gallbladder (cholecystitis). In the trials behind the FDA-approved versions, these events were uncommon, but they did occur more often than with placebo. Part of the explanation is the weight loss itself, because losing weight quickly is a known gallstone risk factor. Understanding why it happens and which symptoms matter lets you and your licensed provider respond early if something changes.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes gallstones as hard, pebble-like pieces of material, usually made of cholesterol or bilirubin, that form in the gallbladder. They are very common, affecting 10 to 15 percent of the US population, and most people who have them never notice any symptoms.
The NIDDK lists several groups who are more likely to develop gallstones:
Many people who start a GLP-1 program already fit one or more of these categories, which is one reason gallbladder health deserves a place in the conversation before treatment begins.
Both FDA-approved labels list acute gallbladder disease in their Warnings and Precautions section. The table below shows what the labels report for adults in the weight-management trials.
| Event | Wegovy (semaglutide) | Placebo | Zepbound (tirzepatide) | Placebo |
|---|---|---|---|---|
| Gallstones (cholelithiasis) | 1.6% | 0.7% | 1.1% | 1.0% |
| Gallbladder inflammation (cholecystitis) | 0.6% | 0.2% | 0.7% | 0.2% |
| Gallbladder removal (cholecystectomy) | not listed here | not listed here | 0.2% | 0% |
In other words, the large majority of trial participants had no gallbladder event at all. The Wegovy label also notes that gallbladder events were more common with the medication than with placebo even after accounting for how much weight people lost, which suggests weight loss does not fully explain the difference.
A broader view comes from a 2022 systematic review and meta-analysis in JAMA Internal Medicine. The authors pooled 76 randomized trials with about 103,000 adults and found that GLP-1 receptor agonist use was associated with a 37 percent higher relative risk of gallbladder or biliary disease (relative risk 1.37). The association was stronger in the 13 trials that used these medications for weight loss (relative risk 2.29), at higher doses (1.56) and with longer treatment (1.40). Lower doses and shorter use showed no clear increase.
Relative risk can sound alarming, so it helps to keep the starting point in mind. A doubling of an uncommon event is still an uncommon event for most people, which is exactly what the label percentages above show.
The NIDDK explains that during fast weight loss the liver releases extra cholesterol into bile, and the gallbladder may not empty as well as it normally does. Both changes favor stone formation. This is why very low-calorie diets and bariatric surgery are also linked to gallstones, and why the NIDDK notes that weight cycling (repeatedly losing and regaining) raises risk too.
GLP-1 medications can produce substantial weight loss, so some of the added gallbladder risk likely comes from that. The label finding that risk stays elevated after accounting for weight loss suggests something more may be involved, and the exact mechanism is still being studied.
According to the NIDDK, a gallbladder attack usually causes pain in the upper right abdomen that can last several hours. Attacks often follow heavy meals and tend to happen in the evening or overnight.
This is different from the mild, come-and-go nausea or fullness many people notice when starting a GLP-1 medication. The NIDDK advises getting care right away if, during or after an attack, you have:
Any severe or persistent abdominal pain while on a GLP-1 medication deserves a prompt call to your licensed provider or a visit to urgent care. If symptoms feel severe or you are worried, call 911.
You cannot control every risk factor, but a few habits line up with the NIDDK guidance:
They are associated with a higher rate of gallstones and gallbladder inflammation than placebo in clinical trials. Some of the effect is likely related to faster weight loss, which raises gallstone risk on its own, but the Wegovy label notes the difference persisted after accounting for weight loss. Most people in the trials did not have a gallbladder event.
In the label data for adults in weight-management trials, gallstones were reported in 1.6 percent of people on Wegovy and 1.1 percent on Zepbound, compared with 0.7 percent and 1.0 percent on placebo. Gallbladder inflammation was reported in under 1 percent of people on either medication. Individual risk varies with personal history and other factors.
A past history does not by itself answer the question; it is one factor a prescriber weighs. Gallbladder disease appears as a warning on both labels, so your clinician will consider your history, symptoms and other risk factors. Be specific about when you had problems and how they were treated.
The data in this article come from FDA-approved products studied in controlled trials. Compounded versions are not FDA-approved, and the FDA states it does not review compounded drugs for safety, effectiveness or quality before they are marketed. Compounded versions were not part of these trials, so their gallbladder risk has not been measured directly. Compounded products available through NewDay Wellness are not FDA-approved, and the same symptom awareness applies.
If you are considering a GLP-1 program, mention any history of gallstones, gallbladder attacks, pancreatitis or rapid weight changes at your first visit, along with any estrogen-containing medications you use. If you are already on treatment and notice pain in the upper right abdomen that lasts for hours, contact your licensed provider promptly, and call 911 in an emergency. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
An underactive thyroid can add modest weight and fatigue, so a TSH test is a sensible check if you have symptoms. Separately, GLP-1 labels warn against use with a personal or family history of medullary thyroid cancer or MEN 2, so share your full thyroid history.
Read article